Northwind Pharmaceuticals

What to Expect from the FDA in 2015

What-to-Expect-from-the-FDA-in-2015The end of the year is coming and 2015 is fast approaching. And as we all start to think about what the New Year will mean for you, what will 2015 hold for pharmaceuticals?

The Federal Drug Administration already has several decisions on the calendar.  According to RTT News,The FDA is so far set to rule on seven proposed medications.


  • RYTARY: for the treatment of idiopathic Parkinson’s disease
  • Triferic:  for treating iron deficiency in chronic kidney disease patients on hemodialysis
  • Triferic: for the treatment of iron replacement and maintenance of hemoglobin in hemodialysis patients


  • Lucentis: for the treatment of diabetic retinopathy
  • Levosert: a hormonal intrauterine contraceptive for use by women to prevent pregnancy.
  • XIFAXAN: for the treatment of irritable bowel syndrome with diarrhea or IBS-D


  • EXPAREL: for use in femoral nerve block for total knee arthroplasty

To read more about the FDA’s 2015 calendar click here.

To stay abreast of all new available medications as well as other points of interest in the constantly-changing world of pharmaceuticals, a reputable partner like Northwind Pharmaceuticals is a great advantage.

Contact us today to see how our solutions can lead to a better 2015.

Schedule a free claims analysis now.

Let’s Talk now


Betsy Bigler | Mar 7th, 2024
INDIANAPOLIS, March 7, 2024 – Northwind has announced the addition of Tony Purkey as Senior Vice President, Client Strategies. “Demand from our self-funded employer and union clients is driving rapid growth,” said Phillip Berry, CEO. “Tony Purkey joins Northwind at a time when we need high-integrity leaders with expert knowledge in employer-sponsored health and the … more »

continue reading

Voices Lost in the Noise

Phillip Berry | Jan 31st, 2024
In the health benefits world, the mad scramble toward January renewals/starts has subsided and attention has turned to the annual cycle of review necessary to gauge progress. How did we do? The plan review process generally centers on analytics to gauge progress or regress and to identify “areas of opportunity.” Good. The right data with … more »

continue reading